The significance of drug-to-lipid ratio to the development of optimized liposomal formulation

References

• Ait-Oudhia S, Mager DE, Straubinger RM. (2014). Application of pharmacokinetic and pharmacodynamic analysis to the development of liposomal formulations for oncology. Pharmaceutics 6:137–74
   PubMedGoogle Scholar
• Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. (2013). Liposome: classification, preparation, and applications. Nanoscale Res Lett 8:102
   PubMed Web of Science ®Google Scholar
• Akhgari A, Heshmati Z, Afrasiabi GH, et al. (2017). Indomethacin electrospun nanofibers for colonic drug delivery: in vitro dissolution studies. Colloids Surf B Biointerfaces 152:29–35
   PubMed Web of Science ®Google Scholar
• Anderson M, Omri A. (2004). The effect of different lipid components on the in vitro stability and release kinetics of liposome formulations. Drug Deliv 11:33–9
   PubMed Web of Science ®Google Scholar
• Barenholz Y. (2003). Relevancy of drug loading to liposomal formulation therapeutic efficacy. J Liposome Res 13:1–8
   PubMed Web of Science ®Google Scholar
• Barenholz Y. (2012). Doxil®-the first FDA-approved nano-drug: lessons learned . J Control Release 160:117–34
   PubMed Web of Science ®Google Scholar
• Bartlett GR. (1959). Phosphorus assay in column chromatography. J Biol Chem 234:466–8
   PubMed Web of Science ®Google Scholar
• Cern A, Golbraikh A, Sedykh A, et al. (2012). Quantitative structure- property relationship modeling of remote liposome loading of drugs. J Control Release 160:147–57
   PubMed Web of Science ®Google Scholar
• Cern A, Barenholz Y, Tropsha A, Goldblumb A. (2014). Computer-aided design of liposomal drugs: in silico prediction and experimental validation of drug candidates for liposomal remote loading. J Control Release 173:125–31
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Shah VP, Klebovich I, et al. (2015). The similarity question for biologicals and non-biological complex drugs. Eur J Pharm Sci 76:10–7
   PubMed Web of Science ®Google Scholar
• Demetzos C, Pippa N. (2013). Advanced drug delivery nanosystems (aDDnSs): a mini-review. Drug Deliv 21: 250–7
   PubMed Web of Science ®Google Scholar
• Demetzos C, Pippa N. (2015). Fractal geometry as a new approach for proving nanosimilarity: a reflection note. Int J Pharm 483:1–5
   PubMed Web of Science ®Google Scholar
• Dutta S, Bhattacharjee P. (2017). Nanoliposomal encapsulates of piperine-rich black pepper extract obtained by enzyme-assisted supercritical carbon dioxide extraction. J Food Eng 201:49–56
   Web of Science ®Google Scholar
• Edwards KA, Baeumner AJ. (2006). Analysis of liposomes 68:1432–41
   Google Scholar
• Ehmann F, Pita R. (2016). The EU is ready for non-biological complex medicinal products. GaBI J 5:30–5
   Google Scholar
• Ehmann F, Sakai-Kato K, Duncan R, et al. (2013). Next-generation nanomedicines and nanosimilars: EU regulators’ initiatives relating to the development and evaluation of nanomedicines. Nanomedicine 8:849–56
   PubMed Web of Science ®Google Scholar
• Eloy JO, Souza MC, Petrilli R, et al. (2014). Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery. Colloids Surf B Biointerfaces 123:345–63
   PubMed Web of Science ®Google Scholar
• Garattini L, Padula A. (2017). Why EMA should provide clearer guidance on the authorization of NBCDs in generic and hybrid applications. Expert Rev Clin Pharmacol 10: 243–5
   PubMed Web of Science ®Google Scholar
• Gubernator J. (2011). Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity. Expert Opin Drug Deliv 8: 565–80
   PubMed Web of Science ®Google Scholar
• Hadjidemetriou M, Pippa N, Pispas S, Demetzos C. (2013). Incorporation of dimethoxycurcumin into charged liposomes and the formation kinetics of fractal aggregates of uncharged vectors. J Liposome Res 23: 94–100
   PubMed Web of Science ®Google Scholar
• Hatziantoniou S, Demetzos C. (2006). Qualitative and quantitative one-step analysis of lipids and encapsulated bioactive molecules in liposome preparations by HPTLC/FID (IATROSCAN). J Liposome Res 16:321–30
   PubMed Web of Science ®Google Scholar
• Hatziantoniou S, Demetzos C. (2017). Method of simultaneous analysis of liposome components using HPTLC/FID. Methods Mol Biol 1522:49–54
   PubMedGoogle Scholar
• Holzschuh S, Kaeß K, Bossa GV, et al. (2016). Investigations of the influence of liposome composition on vesicle stability and drug transfer in human plasma: a transfer study. J Liposome Res 23:1–13
   Google Scholar
• Johnston MJ, Semple SC, Klimuk SK, et al. (2006). Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations. Biochim Biophys Acta 1758: 55–64
   PubMed Web of Science ®Google Scholar
• Johnston MJW, Edwards K, Karlsson G, Cullis PR. (2008). Influence of drug-to-lipid ratio on drug release properties and liposome integrity in liposomal doxorubicin formulations. J Liposome Res 18:145–57
   PubMed Web of Science ®Google Scholar
• Kepczynski M, Nawalany K, Kumorek M, et al. (2008). Which physical and structural factors of liposome carriers control their drug-loading efficiency? Chem Phys Lipids 155:7–15
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, et al. (2014). Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomed 9:4387–98
   PubMed Web of Science ®Google Scholar
• Kulkarni SB, Betageri GV, Singh M. (1995). Factors affecting microencapsulation of drugs in liposomes. J Microencapsul 12:229–46
   PubMed Web of Science ®Google Scholar
• Lila ASA, Ishida T. (2017). Liposomal delivery systems: design optimization and current applications. Biol Pharm Bull 40:1–10
   PubMed Web of Science ®Google Scholar
• Lu Y, Park K. (2013). Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int J Pharm 453:198–214
   PubMed Web of Science ®Google Scholar
• Matsingou C, Demetzos C. (2007). The perturbing effect of cholesterol on the interaction between labdanes and DPPC bilayers. Thermochim Acta 452:116–23
   Web of Science ®Google Scholar
• Mayer LD, Tai LCL, Ko DSC, et al. (1989). Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res 49:5922–30
   PubMed Web of Science ®Google Scholar
• Ong SGM, Ming LC, Lee KS, Yuen KH. (2016). Influence of the encapsulation efficiency and size of liposome on the oral bioavailability of griseofulvin-loaded liposomes. Pharmaceutics 8:25
   PubMed Web of Science ®Google Scholar
• Papaluca M, Ehmann F, Pita R, Hernan D. 2017. Regulatory issues in nanomedicines. In: Cornier J, Kwade A, Owen A, Van de Voorde M, eds. Pharmaceutical nanotechnology: innovation and production: innovation and production. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, Germany, 497–520
   Google Scholar
• Pattni BS, Chupin VV, Torchilin VP. (2015). New developments in liposomal drug delivery. Chem. Rev 115:10938–66
   PubMed Web of Science ®Google Scholar
• Pereira S, Egbu R, Jannati G, Al-Jamal WT. (2016). Docetaxel-loaded liposomes: The effect of lipid composition and purification on drug encapsulation and in vitro toxicity. Int J Pharm 514:150–9
   PubMed Web of Science ®Google Scholar
• Pippa N, Merkouraki M, Pispas S, Demetzos C. (2013a). DPPC:MPOx chimeric advanced Drug Delivery nano Systems (chi-aDDnSs): physicochemical and structural characterization, stability and drug release studies. Int J Pharm 450: 1–10
   PubMed Web of Science ®Google Scholar
• Pippa N, Psarommati F, Pispas S, Demetzos C. (2013b). The shape/morphology balance: a study of stealth liposomes via fractal analysis and drug encapsulation. Pharm Res 30:2385–95
   PubMed Web of Science ®Google Scholar
• Pippa N, Meristoudi A, Pispas S, Demetzos C. (2015). Temperature-dependent drug release from DPPC:C12H25-PNIPAM-COOH liposomes: control of the drug loading/release by modulation of the nanocarriers' components. Int J Pharm 485:374–82
   PubMed Web of Science ®Google Scholar
• Schellekens H, Stegemann S, Weinstein V, et al. (2014). How to regulate nonbiological complex drugs (NBCD) and their follow-on versions: points to consider. AAPS J 16:15–21
   PubMed Web of Science ®Google Scholar
• Simão AMS, Bolean M, Cury TAC, et al. (2015). Liposomal systems as carriers for bioactive compounds. Biophys Rev 7:391–7
   PubMedGoogle Scholar
• Stewart JCM. (1980). Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem 104:10–4
   PubMed Web of Science ®Google Scholar
• Straubinger RM, Balasubramanian SV. (2005). Preparation and characterization of taxane-containing liposomes. Liposomes 391:97–117
   Google Scholar
• Sylvester B, Porfire A, Muntean DM, et al. (2016). Optimization of prednisolone-loaded long-circulating liposomes via application of Quality by Design (QbD) approach. J Liposome Res 26:1–13
   PubMedGoogle Scholar
• Szoka FJ, Papahadjopoulos D. (1980). Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng 9:467–508
   PubMedGoogle Scholar
• Wagner A, Vorauer-Uhl K, Katinger H. (2002). Liposomes produced in a pilot scale: production, purification and efficiency aspects. Eur J Pharm Biopharm 54:213–9
   PubMed Web of Science ®Google Scholar
• Wagner A, Platzgummer M, Kreismayr G, et al. (2006). GMP production of liposomes – a new industrial approach. J Liposome Res 16:311–9
   PubMed Web of Science ®Google Scholar
• Wagner A, Vorauer-Uhl K. (2011). Liposome technology for industrial purposes. J Drug Deliv 2011:591325. doi: 10.1155/2011/591325
   PubMedGoogle Scholar
• Xu X, Khan MA, Burgess DJ. (2011). A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment. Int J Pharm 419:52–9
   PubMed Web of Science ®Google Scholar
• Xu X, Costa AP, Khan MA, Burgess DJ. (2012a). Application of quality by design to formulation and processing of protein liposomes. Int J Pharm 434:349–59
   PubMed Web of Science ®Google Scholar
• Xu X, Khan MA, Burgess DJ. (2012b). A quality by design (QbD) case study on liposomes containing hydrophilic API: II. Screening of critical variables, and establishment of design space at laboratory scale. Int J Pharm 423: 543–53
   PubMed Web of Science ®Google Scholar
• Zheng N, Sun DD, Zou P, Jiang W. (2017). Scientific and regulatory considerations for generic complex drug products containing nanomaterials. AAPS J 19:619–31
   PubMed Web of Science ®Google Scholar
• Zucker D, Marcus D, Barenholz Y, Goldblum A. (2009). Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. J Control Release 139:73–80
   PubMed Web of Science ®Google Scholar